BRPI0802241A2 - células-tronco mesenquimais e seus usos - Google Patents

células-tronco mesenquimais e seus usos Download PDF

Info

Publication number
BRPI0802241A2
BRPI0802241A2 BRPI0802241-0A BRPI0802241A BRPI0802241A2 BR PI0802241 A2 BRPI0802241 A2 BR PI0802241A2 BR PI0802241 A BRPI0802241 A BR PI0802241A BR PI0802241 A2 BRPI0802241 A2 BR PI0802241A2
Authority
BR
Brazil
Prior art keywords
stem cells
mesenchymal stem
animal
promotes
fibrosis
Prior art date
Application number
BRPI0802241-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Sudeepta Aggarwal
Mark F Pittenger
Timothy Varney
Alla Danilkovitch
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of BRPI0802241A2 publication Critical patent/BRPI0802241A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cardiology (AREA)
BRPI0802241-0A 2007-03-22 2008-03-21 células-tronco mesenquimais e seus usos BRPI0802241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/726,676 US20080095749A1 (en) 2004-03-22 2007-03-22 Mesenchymal stem cells and uses therefor
PCT/US2008/057828 WO2008116157A2 (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Publications (1)

Publication Number Publication Date
BRPI0802241A2 true BRPI0802241A2 (pt) 2011-08-30

Family

ID=39735516

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0802241-0A BRPI0802241A2 (pt) 2007-03-22 2008-03-21 células-tronco mesenquimais e seus usos

Country Status (10)

Country Link
US (3) US20080095749A1 (cg-RX-API-DMAC7.html)
EP (6) EP3653217B1 (cg-RX-API-DMAC7.html)
JP (2) JP2010522212A (cg-RX-API-DMAC7.html)
KR (7) KR20090122415A (cg-RX-API-DMAC7.html)
CN (1) CN101626772A (cg-RX-API-DMAC7.html)
BR (1) BRPI0802241A2 (cg-RX-API-DMAC7.html)
CA (2) CA3134185A1 (cg-RX-API-DMAC7.html)
DK (1) DK2123747T3 (cg-RX-API-DMAC7.html)
ES (3) ES2988291T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008116157A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239897A1 (en) 2004-03-22 2005-10-27 Pittenger Mark F Mesenchymal stem cells and uses therefor
WO2005097147A1 (en) * 2004-03-30 2005-10-20 Boston Scientific Limited (Incorporated In Ireland) Restenosis therapy using mesenchymal stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
PT1926813T (pt) 2005-09-23 2016-09-06 Consejo Superior Investigacion Populações de células que têm atividade imunorreguladora, método para isolamento e usos
MX343814B (es) 2005-10-13 2016-11-24 Anthrogenesis Corp Inmunomodulación usando celulas madre de la placenta.
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
EP1971679B1 (en) 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
CN101657206B (zh) 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
WO2009134429A2 (en) * 2008-05-02 2009-11-05 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
US8728805B2 (en) 2008-08-22 2014-05-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2346358A4 (en) * 2008-10-05 2013-11-27 Hymie Friedlander EXTRACT OF ON THE BASIS OF REGENERATIVE CELLS CULTURED CONDITIONED MEDIUM
NZ592726A (en) 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
JP5035737B2 (ja) * 2009-12-07 2012-09-26 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
CA2784847C (en) * 2009-12-18 2017-11-21 Molly Sandra Shoichet Injectable polymer composition for use as a cell delivery vehicle
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
KR101677293B1 (ko) * 2010-04-16 2016-11-17 서울대학교병원 줄기세포의 활성을 증가시키는 방법 및 상기 방법에 의해 제조된 고활성 줄기 세포
CA2798895A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
CN101991880A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga/tcp和msc组成的制剂及其应用
CN101991878A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga和msc组成的制剂及其应用
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
KR101947699B1 (ko) * 2011-03-11 2019-02-14 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
EP2714059B1 (en) 2011-06-01 2018-10-03 Celularity, Inc. Treatment of pain using placental stem cells
CN104136034B (zh) * 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
US20150110751A1 (en) * 2012-05-16 2015-04-23 Kennedy Krieger Institute, Inc. Stem cells as an individualized maternal therapy for prevention of prematurity
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CN115919901A (zh) * 2012-12-12 2023-04-07 麦瑟布莱斯特公司 治疗或预防呼吸病症的方法
ES2742035T3 (es) * 2012-12-12 2020-02-12 Mesoblast Inc Tratamiento de las enfermedades de la disfunción y la inflamación endotelial
EP2934578B1 (en) * 2012-12-24 2018-11-21 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
JP6571537B2 (ja) * 2013-03-13 2019-09-04 ザ ユニバーシティー オブ クイーンズランド 療法および予防のための細胞を単離する方法
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
JP6210049B2 (ja) 2014-11-04 2017-10-11 トヨタ自動車株式会社 車両
RS58977B1 (sr) * 2015-01-08 2019-08-30 Apceth Gmbh & Co Kg Genetički modifikovane mezenhimske matične ćelije koje ekprimiraju alfa-1 antitripsin (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
US10746729B2 (en) * 2015-04-24 2020-08-18 Tigenix, S.A.U. Biomarkers for determining the clinical response to cell therapy
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
WO2017106899A2 (en) * 2015-12-22 2017-06-29 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
KR101970642B1 (ko) * 2016-04-06 2019-05-17 주식회사 제이제이메이딘 줄기세포 배양용 배지조성물 및 그를 이용한 줄기세포 배양방법
EP3450548A4 (en) 2016-04-27 2019-11-20 Rohto Pharmaceutical Co., Ltd. MESCHYMAL STEM CELL FOR EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP OF CD201, CD46, CD56, CD147 AND CD165, AND METHOD FOR THE MANUFACTURE THEREOF AND PHARMACEUTICAL COMPOSITION WITH THE MESENCHYMAL STEM CELL AND METHOD FOR THE PRODUCTION THEREOF
WO2018026203A1 (ko) 2016-08-05 2018-02-08 한양대학교 에리카산학협력단 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN106492194A (zh) * 2016-11-30 2017-03-15 广州赛莱拉干细胞科技股份有限公司 一种干细胞外泌体制剂及其制备方法和应用
CN110366597B (zh) 2016-12-20 2024-03-29 善威生物私人有限公司 用蛋白酶抑制剂进行血液图谱分析
EP3583945A4 (en) * 2017-02-15 2020-11-18 Rohto Pharmaceutical Co., Ltd. PULMONARY FIBROSIS TREATMENT AGENT, PTPRR EXPRESSION PROMOTIONER, AND PULMONARY FIBROSIS TREATMENT KIT
JP2020511464A (ja) 2017-03-15 2020-04-16 オルカ バイオシステムズ インコーポレイテッド 造血幹細胞移植用の組成物および方法
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation CELL POPULATION INCLUDING ADHESIVE STEM CELLS, ITS PRODUCTION PROCESS, AND PHARMACEUTICAL COMPOSITION
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
WO2020015264A1 (zh) * 2018-07-17 2020-01-23 北京三有利和泽生物科技有限公司 牙源干细胞及其用途
US20220154147A1 (en) * 2019-03-12 2022-05-19 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
JP7638529B2 (ja) * 2019-03-21 2025-03-04 アンテロジェン シーオー．，エルティーディー． 間葉系幹細胞－ヒドロゲルを含有する注射用組成物、並びにその製造、凍結及び解凍方法
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
CN110772537A (zh) * 2019-11-07 2020-02-11 深圳科康干细胞技术有限公司 脐带血间充质干细胞组合物在治疗慢性阻塞性肺疾病中的应用
WO2021176001A1 (en) * 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
KR20220164741A (ko) * 2020-04-03 2022-12-13 메조블라스트 인터내셔널 에스에이알엘 중간엽 계통 전구세포 또는 줄기세포를 이용한 과염증 치료 방법
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111568930A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节nk细胞数量的应用
US20230310507A1 (en) * 2020-07-20 2023-10-05 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
WO2024033462A1 (en) * 2022-08-11 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
CN117398450B (zh) * 2023-10-31 2025-03-11 北京三有利和泽生物科技有限公司 过表达肝细胞生长因子的间充质干细胞在制备哮喘药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
SG47041A1 (en) * 1992-03-23 1998-03-20 Bender James G In vitro-derived human neutrophil precursor cells
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
PT1066052E (pt) * 1998-03-18 2006-06-30 Osiris Therapeutics Inc Celulas estaminais mesenquimatosas para a prevencao e tratamento
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DK1066060T3 (da) * 1998-04-03 2003-11-24 Osiris Therapeutics Inc Mesenkymale stamceller som immunsuppresive midler
US6835377B2 (en) * 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
ATE382681T1 (de) * 1998-07-31 2008-01-15 Genzyme Corp Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
WO2002008389A2 (en) * 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
CN1615143A (zh) * 2002-01-14 2005-05-11 亨利·福特卫生系统 来自骨髓基质细胞的用于形成血管并产生血管生成和营养因子的物质
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
US20050239897A1 (en) * 2004-03-22 2005-10-27 Pittenger Mark F Mesenchymal stem cells and uses therefor
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
WO2006112365A1 (ja) * 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
CA2705450A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al Stem cells for treating lung diseases
US8029805B2 (en) 2008-07-25 2011-10-04 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Recombinant B. pseudomallei adhesin protein and methods and uses thereof

Also Published As

Publication number Publication date
KR20220166876A (ko) 2022-12-19
EP4438721A2 (en) 2024-10-02
HK1136601A1 (en) 2010-07-02
US20080095749A1 (en) 2008-04-24
KR20160027230A (ko) 2016-03-09
JP5961220B2 (ja) 2016-08-02
CA2637157C (en) 2021-11-23
EP3095450B1 (en) 2019-10-23
KR102519603B1 (ko) 2023-04-10
WO2008116157A2 (en) 2008-09-25
KR20240008404A (ko) 2024-01-18
US20090220464A1 (en) 2009-09-03
EP2123747A1 (en) 2009-11-25
KR20250052468A (ko) 2025-04-18
EP2123747B1 (en) 2016-06-08
US20100330048A1 (en) 2010-12-30
JP2010522212A (ja) 2010-07-01
JP2014224117A (ja) 2014-12-04
CA2637157A1 (en) 2008-09-21
CA3134185A1 (en) 2008-09-21
ES2891574T3 (es) 2022-01-28
EP4438721A3 (en) 2025-04-02
KR20220018084A (ko) 2022-02-14
ES2765650T3 (es) 2020-06-10
EP3095450A1 (en) 2016-11-23
EP3653217A1 (en) 2020-05-20
WO2008116157A3 (en) 2009-03-19
EP3653217B1 (en) 2021-09-08
ES2988291T3 (es) 2024-11-20
EP3973970A1 (en) 2022-03-30
EP3973970B1 (en) 2024-08-28
CN101626772A (zh) 2010-01-13
KR20190031346A (ko) 2019-03-25
KR102357942B1 (ko) 2022-02-03
DK2123747T3 (en) 2016-07-04
EP2051718A2 (en) 2009-04-29
KR20090122415A (ko) 2009-11-30

Similar Documents

Publication Publication Date Title
BRPI0802241A2 (pt) células-tronco mesenquimais e seus usos
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
WO2008042174A3 (en) Mesenchymal stem cells and uses therefor
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112013005300A2 (pt) composições que compreendem extratos ácidos da goma mástique
BR112013000537A2 (pt) composição aquosa contendo bromexina
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
BRPI1011710B8 (pt) composição para ser usada como uma lágrima artificial
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
PA8780101A1 (es) Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
DOP2008000018A (es) Anticuerpos anti-ige
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
BRPI0803568B8 (pt) composição mucoaderente
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
BR112015024920A2 (pt) associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BR112016015641A2 (pt) Composições e métodos de tratamento de condições patológicas inflamatórias da pele usando alantoína

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25A Requested transfer of rights approved

Owner name: MESOBLAST INTERNATIONAL SARL (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 35/28 (2015.01), C12N 5/0775 (2010.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]